Sam Brusco, Associate Editor07.18.23
NAMSA, a medtech contract research organization (CRO), has acquired CRI – The Clinical Research Institute, a German full-service CRO. The transaction’s terms were not disclosed.
CRI provides the European medtech market with clinical research solutions to accelerate scientific outcomes. The researchers use their expertise across clinical research and data solutions to support customers along the clinical research continuum.
“We are delighted to welcome CRI to NAMSA,” Dr. Christophe Berthoux, NAMSA CEO told the press. “The addition of this organization to the NAMSA family is a significant move for us in Germany that enhances and expands our CRO offerings throughout Europe and across all markets. This exciting acquisition presents new opportunities for us to fulfill our mission of saving patients' lives.”
NAMSA’s clinical research services include clinical study management, post market studies, biostatistics and data management, safety reporting, and imaging core lab services. The company’s broad range of experience leads through all phases of clinical research, from first-in-human to pivotal and post-market studies.
“CRI is an unmatched partner for NAMSA, as both companies share identical values and are wholeheartedly committed to delivering unparalleled service and resources to the medical device and diagnostic sectors,” declared Dr. Thomas Fetsch, CRI CEO. “With a team of seasoned experts well versed in the fields of medicine and science, CRI is thrilled to join forces with NAMSA to bolster their global presence, particularly in Europe.”
“Together, the collective proficiency of both organizations will establish them as the foremost MedTech CRO for Cardiovascular research services across the globe,” added Elisabeth Freund, CRI Founder. “I am confident in the abilities of our teams to leverage expertise and continue to deliver superior results to our global clients.”
NAMSA began a strategic outsourcing partnership with Terumo Aortic last month.
CRI provides the European medtech market with clinical research solutions to accelerate scientific outcomes. The researchers use their expertise across clinical research and data solutions to support customers along the clinical research continuum.
“We are delighted to welcome CRI to NAMSA,” Dr. Christophe Berthoux, NAMSA CEO told the press. “The addition of this organization to the NAMSA family is a significant move for us in Germany that enhances and expands our CRO offerings throughout Europe and across all markets. This exciting acquisition presents new opportunities for us to fulfill our mission of saving patients' lives.”
NAMSA’s clinical research services include clinical study management, post market studies, biostatistics and data management, safety reporting, and imaging core lab services. The company’s broad range of experience leads through all phases of clinical research, from first-in-human to pivotal and post-market studies.
“CRI is an unmatched partner for NAMSA, as both companies share identical values and are wholeheartedly committed to delivering unparalleled service and resources to the medical device and diagnostic sectors,” declared Dr. Thomas Fetsch, CRI CEO. “With a team of seasoned experts well versed in the fields of medicine and science, CRI is thrilled to join forces with NAMSA to bolster their global presence, particularly in Europe.”
“Together, the collective proficiency of both organizations will establish them as the foremost MedTech CRO for Cardiovascular research services across the globe,” added Elisabeth Freund, CRI Founder. “I am confident in the abilities of our teams to leverage expertise and continue to deliver superior results to our global clients.”
NAMSA began a strategic outsourcing partnership with Terumo Aortic last month.